Personal information

Other IDs

Scopus Author ID: 56082352000
ResearcherID: F-7229-2017

Activities

Collapse all

Employment (1)

Benemérita Universidad Autónoma de Puebla: Puebla, Puebla, MX

2011-09-16 to present | Head of Technology Transfer (Dirección de Innovación y Transferencia de Conocimiento)
Employment
Source: Self-asserted source
Martin Perez-Santos

Education and qualifications (1)

Centro de Investigacion y de Estudios Avanzados del Instituto Politecnico Nacional: Mexico, Mexico, MX

1997-07-01 to 2001-11-15 | PhD (Patologia Experimental)
Education
Source: Self-asserted source
Martin Perez-Santos

Works (42)

Trispecific anti-CD3/BCMA/CD38 antibodies for multiple myeloma: a patent evaluation of US20240132615

Expert Opinion on Therapeutic Patents
2025-01-02 | Journal article
DOI: 10.1080/13543776.2024.2423018
Contributors: Cindy Bandala; Donaciano Flores-Robles; Pavel Sierra-Martínez; Alejandro Millán-Vega; Eunice Ruíz González; Martin Perez-Santos
Source: check_circle
Crossref

Nivel de madurez tecnológica de patentes otorgadas a instituciones del sector de salud público de México

Inventio
2024-12-12 | Journal article
DOI: 10.30973/inventio/2024.20.51/2
Contributors: Martin Perez-Santos; Maricruz Anaya-Ruiz
Source: Self-asserted source
Martin Perez-Santos
grade
Preferred source (of 2)‎

Patenting Trends by Mexican Pharmaceutical Companies

Pharmaceutical Patent Analyst
2023-11 | Journal article
DOI: 10.4155/ppa-2023-0029
Contributors: Luis Villafaña-Diaz; Juan C Perez-Garcia; Diana Barron-Villaverde; Martin Perez-Santos
Source: check_circle
Crossref

Drug repurposing of rimantadine for treatment of cancer.

Pharmaceutical patent analyst
2023-11-20 | Journal article | Author
DOI: 10.4155/ppa-2023-0019
PMID: 37982658
Contributors: Villa-Ruano N; Vianey Marín-Cevada; Gabriela Sánchez Esgua; Luis Villafaña; Martin Perez-Santos
Source: Self-asserted source
Martin Perez-Santos
grade
Preferred source (of 2)‎

Drug Repurposing of Mito-Atovaquone for Cancer Treatment

Pharmaceutical Patent Analyst
2023-07 | Journal article
DOI: 10.4155/ppa-2023-0015
Contributors: Nemesio Villa-Ruano; Maricruz Anaya-Ruiz; Luis Villafaña-Diaz; Diana Barron-Villaverde; Martin Perez-Santos
Source: check_circle
Crossref

Estrogens as a Possible Therapeutic Strategy for the Management of Neuroinflammation and Neuroprotection in COVID-19

Current Neuropharmacology
2023-06-16 | Journal article
DOI: 10.2174/1570159x21666230616103850
Part of ISSN: 1570-159X
Contributors: Cindy Bandala; Eleazar Lara-Padilla; Noemí Cárdenas-Rodríguez; Samuel Reyes-Long; Alfredo Cortés-Algara; Itzel Jatziri Contreras-García; Teresita Rocío Cruz-Hernández; Alfonso Alfaro-Rodriguez; José Luis Cortes-Altamirano; Martín Perez-Santos et al.
Source: Self-asserted source
Martin Perez-Santos

Patenting Trends in the Pharmaceutical Field of Mexican Universities

Pharmaceutical Patent Analyst
2023-01 | Journal article
DOI: 10.4155/ppa-2022-0048
Contributors: Gabriela Sanchez-Esgua; Juan Reyes-Alvarez; Martin Perez-Santos
Source: check_circle
Crossref

Pharmaceutical agents for the treatment of Chagas disease: patenting trends in the 2016-2021 period

Pharmaceutical Patent Analyst
2022 | Journal article
DOI: 10.4155/PPA-2022-0005
WOSUID: WOS:000830663600002
Contributors: Flores-Quiroz, Viridiana, I; Zumaquero-Rios, Lino; Perez-Santos, Martin
Source: check_circle
Web of Science Researcher Profile Sync
grade
Preferred source (of 2)‎

Approaches for development of LAG-3 inhibitors and the promise they hold as anticancer agents

Expert Opinion on Drug Discovery
2022-12-02 | Journal article
DOI: 10.1080/17460441.2022.2148652
Contributors: Martin Perez-Santos; Maricruz Anaya-Ruiz; Luis Villafaña-Diaz; Gabriela Sánchez Esgua
Source: check_circle
Crossref

Drug Repurposing of Adapalene for Melanoma Treatment

Pharmaceutical Patent Analyst
2022-01 | Journal article
DOI: 10.4155/ppa-2021-0021
Contributors: Maricruz Anaya-Ruiz; Martin Perez-Santos
Source: check_circle
Crossref

Small-Molecule Inhibitor PD-1/PD-L1 Interaction for Colorectal Cancer Treatment

Pharmaceutical Patent Analyst
2021-11 | Journal article
DOI: 10.4155/ppa-2021-0016
Contributors: Maricruz Anaya-Ruiz; Martin Perez-Santos
Source: check_circle
Crossref

Bispecific Anti-OX40/5T4 Antibodies for Cancer Treatment

Pharmaceutical Patent Analyst
2021-03 | Journal article
DOI: 10.4155/ppa-2020-0030
Contributors: Martin Perez-Santos
Source: check_circle
Crossref

Treatment of Solid Tumors Using Bispecific Anti-PDL-1/ICOS Antibody

Pharmaceutical Patent Analyst
2021-03 | Journal article
DOI: 10.4155/ppa-2020-0035
Contributors: Martin Perez-Santos; Maricruz Anaya-Ruiz; Gabriela Sanchez-Esgua; Luis Villafaña-Diaz; Diana Barron-Villaverde
Source: check_circle
Crossref

Neurophysiological Mechanisms Related to Pain Management in Bone Tumors.

Current Neuropharmacology
2021-03-14 | Journal article
DOI: 10.2174/1570159x18666201111112748
PMID: 33176655
Source: Self-asserted source
Martin Perez-Santos

OX40 agonists for cancer treatment: a patent review

Expert Opinion on Therapeutic Patents
2021-01-02 | Journal article
DOI: 10.1080/13543776.2021.1825688
Contributors: Jorge Cebada; Martin Perez-Santos; Cindy Bandala; Eleazar Lara-Padilla; Irma Herrera-Camacho; Nora Hilda Rosas-Murrieta; Lourdes Millán-Pérez Peña; Eduardo Monjaraz; Amira Flores; Maricruz Anaya-Ruiz
Source: check_circle
Crossref

Bispecific anti-PD-L1/PD-1 antibodies for advanced solid tumors: a patent evaluation of US2019010232

Expert Opinion on Therapeutic Patents
2020-10-02 | Journal article
DOI: 10.1080/13543776.2020.1810238
Contributors: Nemesio Villa-Ruano; Tayde Guerrero-González; Eduardo Gómez-Conde; Martin Perez-Santos
Source: check_circle
Crossref

Bispecific anti-PD-1/CTLA-4 Antibody for Advanced Solid Tumors

Pharmaceutical Patent Analyst
2020-09 | Journal article
DOI: 10.4155/ppa-2020-0017
Contributors: Martin Perez-Santos
Source: check_circle
Crossref

Bispecific anti-PD-1/LAG-3 antibodies for treatment of advanced or metastatic solid tumors: a patent evaluation of US2018326054

Expert Opinion on Therapeutic Patents
2020-07-02 | Journal article
DOI: 10.1080/13543776.2020.1767071
Contributors: Jorge Cebada; Amira Flores; Cindy Bandala; Ian Lizaliturri-Flores; Nemesio Villa-Ruano; Martin Perez-Santos
Source: check_circle
Crossref

Colon carcinoma treatment using bispecific anti-GITR/CTLA-4 antibodies: a patent evaluation of WO2018091739

Expert Opinion on Therapeutic Patents
2020-05-03 | Journal article
DOI: 10.1080/13543776.2020.1732352
Contributors: Lourdes Millán-Pérez Peña; Perez-Santos Martin; Irma Herrera-Camacho; Cindy Bandala; Maricruz Anaya-Ruiz
Source: check_circle
Crossref

Treatment of cancer with an anti-KIR antibody: a patent evaluation of US9879082 and US2018208652

Expert Opinion on Therapeutic Patents
2020-03-03 | Journal article
DOI: 10.1080/13543776.2020.1717469
Contributors: Martin Perez-Santos; Tayde Guerrero-González; Eduardo Gómez-Conde; Jorge Cebada; Amira Flores; Nemesio Villa-Ruano
Source: check_circle
Crossref

Cancer combinatorial immunotherapy using etigilimab and nivolumab: a patent evaluation of WO2018102536

Expert Opinion on Therapeutic Patents
2020-02-01 | Journal article
DOI: 10.1080/13543776.2020.1709445
Contributors: Martin Perez-Santos; Maricruz Anaya-Ruiz; Irma Herrera-Camacho; Nora Hilda Rosas-Murrieta; Lourdes Millán-Pérez Peña
Source: check_circle
Crossref

Bispecific anti-OX40/CTLA-4 antibodies for advanced solid tumors: a patent evaluation of WO2018202649

Expert Opinion on Therapeutic Patents
2019-12-02 | Journal article
DOI: 10.1080/13543776.2019.1681400
Contributors: Martin Perez-Santos; Maricruz Anaya-Ruiz; Irma Herrera-Camacho; Lourdes Millán-Pérez Peña; Nora Hilda Rosas-Murrieta
Source: check_circle
Crossref

Cancer immunotherapy using anti-TIM3/PD-1 bispecific antibody: a patent evaluation of EP3356411A1

Expert Opinion on Therapeutic Patents
2019-08-03 | Journal article
DOI: 10.1080/13543776.2019.1637422
Contributors: Irma Herrera-Camacho; Maricruz Anaya-Ruiz; Martin Perez-Santos; Lourdes Millán-Pérez Peña; Cindy Bandala; Gerardo Landeta
Source: check_circle
Crossref

LAG-3 antagonists by cancer treatment: a patent review

Expert Opinion on Therapeutic Patents
2019-08-03 | Journal article
DOI: 10.1080/13543776.2019.1642873
Contributors: Martin Perez-Santos; Maricruz Anaya-Ruiz; Jorge Cebada; Cindy Bandala; Gerardo Landeta; Patricia Martínez-Morales; Nemesio Villa-Ruano
Source: check_circle
Crossref

Cancer combinatorial immunotherapy using anti-OX40 agonist and anti-PD-L1 antagonist: a patent evaluation of US2018256711A1

Expert Opinion on Therapeutic Patents
2019-07-03 | Journal article
DOI: 10.1080/13543776.2019.1634690
Contributors: Martin Perez-Santos; Maricruz Anaya-Ruiz; Irma Herrera-Camacho; Lourdes Millán-Pérez Peña
Source: check_circle
Crossref

Treatment of cancer with a combination of LAG-3Ig and anti-PD-1/anti-PD-L1 antibodies: a patent evaluation of US2018271940 A1

Expert Opinion on Therapeutic Patents
2019-05-04 | Journal article
DOI: 10.1080/13543776.2019.1608947
Contributors: Martin Perez-Santos; Maricruz Anaya-Ruiz; Jorge Cebada; Irma Herrera-Camacho
Source: check_circle
Crossref

Nanostructured Systems in Advanced Drug Targeting for the Cancer Treatment: Recent Patents An Increasing Interest in Nanoparticles in Cancer

Recent Patent on Anti-Cancer Drug Discovery
2018-10-31 | Journal article
DOI: 10.2174/1574892813666181031154146
PMID: 30381087
Source: Self-asserted source
Martin Perez-Santos

Emerging Drugs for the Treatment of Breast Cancer Brain Metastasis: A Review of Patent Literature

Recent Patents on Anti-Cancer Drug Discovery
2018-09-31 | Journal article
DOI: 10.2174/1574892813666180430113605
PMID: 29708077
Source: Self-asserted source
Martin Perez-Santos

Bursera copallifera Extracts Have Cytotoxic and Migration-Inhibitory Effects in Breast Cancer Cell Lines

Integrative Cancer Therapies
2018-09-30 | Journal article
DOI: 10.1177/1534735418766416
PMID: 29652200
Source: Self-asserted source
Martin Perez-Santos

Contribution of Latin American Countries to Cancer Research and Patent Generation: Recent Patents

Recent Patents on Anti-Cancer Drug Discovery
2017 | Journal article
DOI: 10.2174/1574892811666161013114413
WOSUID:

WOS:000397249100008

PMID: 27739356
Source: Self-asserted source
Martin Perez-Santos
grade
Preferred source (of 3)‎

Immunization with excretion-secretion products of Trichinella spiralis combined to CTLA-4 blockade produces a high degree of protection against a challenge with the parasite | La inmunización con productos de excreción-secreción de Trichinella spiralis unido al bloqueo de CTLA-4 produce un elevado grado de protección ante un reto con el parásito

VacciMonitor
2017 | Journal article
EID:

2-s2.0-85017223908
Contributors: Zumaquero-Ríos, J.L.; Pérez-Santos, M.; Villa-Mancera, A.; Sarracent-Pérez, J.
Source: Self-asserted source
Martin Perez-Santos via Scopus - Elsevier

Synaptic vesicle protein isoforms (SV2A, SV2B, SV2C): Expression in breast cancer and their association with risk factors and metastasis in Mexican women

International Journal of Clinical and Experimental Pathology
2017 | Journal article
EID:

2-s2.0-85014049661

WOSUID:

WOS:000395739000130
Source: Self-asserted source
Martin Perez-Santos
grade
Preferred source (of 2)‎

Alternative splicing in breast cancer and the potential development of therapeutic tools

Genes
2017-10-05 | Journal article
DOI: 10.3390/genes8100217
EID:

2-s2.0-85031283422

PMID: 28981467
WOSUID:

WOS:000414862300001
Source: Self-asserted source
Martin Perez-Santos
grade
Preferred source (of 2)‎

Innovation Status of Gene Therapy for Breast Cancer

Asían Pacific Journal of Cancer Prevention
2015-05 | Journal article
DOI: 10.7314/APJCP.2015.16.9.4133
PMID: 25987099
Source: Self-asserted source
Martin Perez-Santos
grade
Preferred source (of 2)‎

Cervical Cancer Trends in Mexico: Incidence, Mortality and Research Output

Asian Pacific Journal of Cancer Prevention
2014-11 | Journal article
DOI: 10.7314/APJCP.2014.15.20.8689 ·
PMID: 25374191
WOSUID:

WOS:000351055100028
Source: Self-asserted source
Martin Perez-Santos
grade
Preferred source (of 2)‎

Female Breast Cancer Incidence and Mortality in Mexico, 2000-2010

Asian Pacific Journal of Cancer Prevention
2014-02 | Journal article
DOI: 10.7314/APJCP.2014.15.3.1477
PMID: 24606486
WOSUID:

WOS:000333669500067
Source: Self-asserted source
Martin Perez-Santos
grade
Preferred source (of 2)‎

Effect of botulinum toxin A on proliferation and apoptosis in the T47D breast cancer cell line

Asian Pacific Journal of Cancer Prevention
2013 | Journal article
DOI: 10.7314/APJCP.2013.14.2.891
EID:

2-s2.0-84877643851

PMID: 23621257
WOSUID:

WOS:000324920000051
Source: Self-asserted source
Martin Perez-Santos
grade
Preferred source (of 2)‎

MiR-485 acts as a tumor suppressor by inhibiting cell growth and migration in breast carcinoma T47D cells

Asian Pacific Journal of Cancer Prevention
2013 | Journal article
DOI: 10.7314/APJCP.2013.14.6.3757
EID:

2-s2.0-84882638790

PMID: 23886178
WOSUID:

WOS:000331517700063
Source: Self-asserted source
Martin Perez-Santos
grade
Preferred source (of 2)‎

Mexican Breast Cancer Research Output, 2003-2012

Asian Pacific Journal of Cancer Prevention
2013-10 | Journal article
DOI: 10.7314/APJCP.2013.14.10.5921
PMID: 24289601
WOSUID:

WOS:000328274200058
Source: Self-asserted source
Martin Perez-Santos
grade
Preferred source (of 2)‎

miR-153 Silencing Induces Apoptosis in the MDA-MB-231 Breast Cancer Cell Line

Asian Pacific Journal of Cancer Prevention
2013-05 | Journal article
DOI: 10.7314/APJCP.2013.14.5.2983
PMID: 23803066
WOSUID:

WOS:000331473400051
Source: Self-asserted source
Martin Perez-Santos
grade
Preferred source (of 2)‎

An ecto-protein tyrosine phosphatase of Entamoeba histolytica induces cellular detachment by disruption of actin filaments in HeLa cells

International Journal for Parasitology
2003-07 | Journal article
DOI: 10.1016/S0020-7519(03)00029-8
PMID: 12814646
WOSUID:

WOS:000183743600001
Source: Self-asserted source
Martin Perez-Santos
grade
Preferred source (of 2)‎

In vitro indomethacin administration upregulates interleukin-12 production and polarizes the immune response towards a Th1 type in susceptible BALB/c mice infected with Leishmania mexicana

Parasite Immunology
2001-11 | Journal article
DOI: 10.1046/j.1365-3024.2001.00421.x
PMID: 11703811
WOSUID:

WOS:000172343200005
Source: Self-asserted source
Martin Perez-Santos
How many people are using ORCID?